Trodelvy: A New Option for Triple-Negative Breast Cancer
Breast cancer is the most common cancer among women worldwide, and about 15% of cases are triple-negative, meaning that the cancer cells do not have receptors (targets) for estrogen, progesterone, or HER2 (a protein that stimulates cell growth and survival).
